Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Next Science Ltd ( (AU:NXS) ) is now available.
Next Science Ltd has issued 465,131 ordinary shares to its Managing Director and CEO, I.V. Hall, as part of the settlement for tranche 2 of the Sign-On Rights. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant legal provisions, indicating a transparent and regulated approach to executive compensation.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science Ltd operates in the medical technology industry, focusing on innovative solutions for infection prevention and treatment. The company is known for its proprietary Xbio technology, which targets biofilm-based infections, a significant challenge in healthcare settings.
YTD Price Performance: 17.39%
Average Trading Volume: 427,599
Technical Sentiment Signal: Sell
Current Market Cap: A$39.44M
Find detailed analytics on NXS stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “Losing the Console Race by Miles”: Microsoft Stock (NASDAQ:MSFT) Ticks Up as the Console Wars Gain a Bit of Clarity
- “…In 18 Months This is a $35,000 Truck” Tesla Stock (NASDAQ:TSLA) Surges With New Pricing Projections
- “Historic Union Busting”: Starbucks Stock (NASDAQ:SBUX) Slips as Strikes Gain Ground, Draw Congress Reps